---
tags:
  - iints/source
  - iints/source/trial
source_id: "adapt_2022_ahcl"
source_bucket: "packaged_evidence"
category: "trial"
component: "aid_benchmarking"
url: "https://doi.org/10.1016/S2213-8587(22)00212-1"
doi: "10.1016/S2213-8587(22)00212-1"
status: active
---

# Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT)

> [!info] What this source supports
> Adds modern AHCL outcomes for realistic comparator ranges.

| Field | Value |
| --- | --- |
| Source ID | `adapt_2022_ahcl` |
| Bucket | `packaged_evidence` |
| Category | `trial` |
| SDK component | `aid_benchmarking` |
| DOI | 10.1016/S2213-8587(22)00212-1 |
| URL | https://doi.org/10.1016/S2213-8587(22)00212-1 |
| Origin file | `src/iints/presets/evidence_sources.yaml` |

## Citation

Benhamou PY, et al. Lancet Diabetes Endocrinol. 2022;10(10):720-731.

## User Interpretation

Use this source to explain **why the SDK default, metric, dataset, or hardware-safety boundary exists**. It is evidence support for pre-clinical simulation and documentation, not a medical approval claim.
